Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!! -- Ignore unavailable to you. Want to Upgrade?

To: Spiney who wrote (49)	12/7/1998 3:27:00 PM
From: Stephen O	Read Replies (1) \| Respond to of 94

NEUROLOGICAL DRUG DEVELOPMENT COLLABORATION This was never posted when it came out on Nov 18th 98 311-2386 East Mall, University of British Columbia Vancouver, B.C. Canada V6T 1Z3 Trading Symbol: IGT Web Site: igtpharma.com Wednesday, November 18, 1998 Contact: Bruce Schmidt at 604-822-3503 or 1-800-743-7444 NEUROLOGICAL DRUG DEVELOPMENT COLLABORATION The Company has formed a collaborative agreement with The Royal Danish School of Pharmacy in Copenhagen to undertake biological screening of IGT's new range of chiral amino acids as novel lead compounds for neurological therapeutic drugs. Using expressed metabotropic glutamate receptors (mGluRs), new drug compounds will initially be screened within Group 1 mGluRs for neuroprotective activity related to the treatment of strokes and head trauma as well as within Group 2 mGluRs for anxiolytic activity for the treatment of anxiety and schizophrenia. Also of interest within the Group 2 screening will be activity related to the treatment of drug addiction. Stroke is the leading cause of adult disability in the western world accounting for 10% of all deaths in men and 16.5% of deaths in women. Estimated costs to treat stroke victims in the United States is $30 billion per year. Anxiety disorders affect about 5% of the population and often long-term treatment is required. Worldwide sales of anxiolytic drugs in 1997 was reported at $2.4 billion This biological testing arrangement is one aspect of a multi-organizational approach to bring more effective neurological drugs to market. The use of mGluR receptors in the brain, will allow IGT to design more specifically acting drugs which will eliminate many of the unwanted side effects present in current treatments. IGT Pharma Inc. is a drug development company focused on new therapeutic approaches for the treatment of cancer and diseases of the central nervous system. IGT is staged to begin human clinical trials for a new lung cancer drug, Anhydrovinblastine. Areas of neurological drug development include the treatment of a range of disorders including schizophrenia, anxiety, stroke, epilepsy, and drug dependence. On behalf of the board of directors of IGT Pharma Inc. Bruce Schmidt President